Has anyone seen any news of a Phase 2 study using Nilotinib?

“To my knowledge, this study represents the first time a therapy appears to reverse — to a greater or lesser degree depending on stage of disease — cognitive and motor decline in patients with these neurodegenerative disorders,” says Pagan. “But it is critical to conduct larger and more comprehensive studies before determining the drug’s true impact.”

http://www.themarketbusiness.com/201...eimers-disease